From: IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19
Laboratory findings | Total (N = 74) | Severe patients (N = 19) | Critically ill patients (N = 55) | P | |||
---|---|---|---|---|---|---|---|
n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | ||
ELISA | |||||||
IP-10, pg/mL | 74 | 364.8 (203.7–939.4) | 19 | 193.1 (123.0–300.5) | 55 | 531.3 (278.0–1217.3) | < 0.001 |
MCP-1, pg/mL | 73 | 642.2 (293.2–1207.5) | 18 | 230.7 (137.9–338.7) | 55 | 837.0 (425.6–1374.0) | < 0.001 |
MIP1a, pg/mL | 74 | 28.6 (15.2–79.7) | 19 | 25.5 (13.8–86.1) | 55 | 30.6 (16.4–77.6) | 0.338 |
Cytokines | |||||||
IL-1β, pg/mL | 29 | 5.0 (5.0–5.0) | 4 | 5.0 (5.0–5.0) | 25 | 5.0 (5.0–5.9) | 0.284 |
IL-2R, U/mL | 30 | 1055.5 (464.5–1609.5) | 5 | 740.0 (325.0–1314.5) | 25 | 1258.0 (518.5–1820.0) | 0.331 |
IL-6, pg/mL | 48 | 74.2 (17.0–157.5) | 13 | 10.4 (5.4–31.1) | 35 | 103.0 (43.0–323.2) | < 0.001 |
IL-8, pg/mL | 29 | 51.7 (12.5–114.7) | 4 | 11.1 (8.1–60.8) | 25 | 62.3 (19.9–142.5) | 0.077 |
IL-10, pg/mL | 29 | 11.4 (5.0–20.1) | 4 | 5.0 (5.0–8.0) | 25 | 11.9 (5.0–25.1) | 0.049 |
TNFα, pg/mL | 27 | 12.7 (7.5–28.7) | 4 | 7.8 (6.4–9.1) | 23 | 13.3 (7.5–30.3) | 0.414 |
Hematologic parameters | |||||||
Platelets, × 109/mL | 72 | 132.5 (70.8–232.0) | 17 | 254.0 (158.5–370.5) | 55 | 88.0 (56.0–191.0) | < 0.001 |
Platelet distribution width (PDW), fL | 64 | 14.4 (12.9–16.6) | 17 | 13.4 (11.5–14.4) | 47 | 14.5 (13.1–18.6) | < 0.001 |
Mean platelet volume (MPV), fL | 64 | 11.6 (11.0–12.6) | 17 | 11.2 (10.3–11.7) | 47 | 11.9 (11.2–13.1) | 0.005 |
Platelet larger cell ratio (P-LCR), % | 64 | 37.9 (33.1–45.2) | 17 | 33.2 (26.9–38.2) | 47 | 40.3 (34.2–47.6) | 0.003 |
Plateletcrit (PCT), % | 64 | 0.19 (0.10–0.26) | 17 | 0.28 (0.19–0.37) | 47 | 0.13 (0.08–0.23) | < 0.001 |
Coagulation function | |||||||
Prothrombin time (PT), s | 71 | 15.9 (14.9–18.2) | 17 | 14.9 (14.0–15.6) | 54 | 16.9 (15.5–18.5) | < 0.001 |
Prothrombin activity (PTA), % | 71 | 69.0 (55.0–80.0) | 17 | 80.0 (72.5–89.0) | 54 | 63.0 (53.3–72.5) | < 0.001 |
International normalized ratio (INR) | 71 | 1.26 (1.15–1.49) | 17 | 1.15 (1.07–1.23) | 54 | 1.36 (1.22–1.54) | < 0.001 |
Fibrinogen (FIB), g/L | 71 | 4.2 (3.1–5.2) | 17 | 4.2 (3.5–4.9) | 54 | 4.2 (3.0–5.3) | 0.845 |
Activated partial thromboplastin time (APTT), s | 71 | 44.5 (39.3–52.6) | 17 | 41.5 (37.0–46.6) | 54 | 46.4 (40.7–53.9) | 0.089 |
Thrombin time (TT), s | 71 | 15.3 (14.5–16.5) | 17 | 15.0 (14.3–15.7) | 54 | 15.5 (14.7–16.9) | 0.083 |
d-dimer, μg/mL FEU | 71 | 3.9 (1.7–13.5) | 17 | 2.4 (1.3–3.6) | 54 | 6.2 (2.3–15.2) | 0.006 |
Fibrin degradation products (FDP), μg/mL | 30 | 17.2 (6.2–68.6) | 6 | 4.9 (4.0–7.8) | 24 | 33.6 (13.6–102.6) | 0.003 |
Antithrombin (AT), % | 34 | 80.5 (65.5–88.5) | 8 | 85.0 (74.3–93.0) | 26 | 78.5 (63.0–86.5) | 0.219 |